Suppression of latent transforming growth factor-β (TGF-β)-binding protein 1 (LTBP1) inhibits natural killer/ T cell lymphoma progression by inactivating the TGF-β/Smad and p38MAPK pathways
Rui Lin(First Affiliated Hospital of Zhengzhou University), Mingzhi Zhang(Chinese Academy of Sciences), Xudong Zhang(Agricultural Genomics Institute at Shenzhen), Xiaoli Li(Hubei University of Arts and Science), Meng Dong(First Affiliated Hospital of Zhengzhou University), Shaoxuan Wu(First Affiliated Hospital of Zhengzhou University), Huting Hou(First Affiliated Hospital of Zhengzhou University), Siyu Qian(First Affiliated Hospital of Zhengzhou University)
Cited by 29
Related Papers
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
|Frontiers in Immunology|2017|296
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
|Journal of Hematology & Oncology|2016|250
Radiation Transfer Model Intercomparison (RAMI) exercise: Results from the second phase
|Journal of Geophysical Research Atmospheres|2004|191
AKR1B1 promotes basal-like breast cancer progression by a positive feedback loop that activates the EMT program
|The Journal of Experimental Medicine|2017|171
miR-137 Is Frequently Down-Regulated in Gastric Cancer and Is a Negative Regulator of Cdc42
|Digestive Diseases and Sciences|2011|140